D
Knight Therapeutics Inc.
GUD.TO
TSX
D
Sell
5/14/2024Downgrade
Knight Therapeutics Inc. (GUD.TO) was downgraded to D- from D on 5/14/2024 due to a decline in the volatility index.
Knight Therapeutics Inc. (GUD.TO) was downgraded to D- from D on 5/14/2024 due to a decline in the volatility index.
D
Sell
4/11/2024Upgraded
Knight Therapeutics Inc. (GUD.TO) was upgraded to D from D- on 4/11/2024 due to an increase in the total return index, volatility index and solvency index.
Knight Therapeutics Inc. (GUD.TO) was upgraded to D from D- on 4/11/2024 due to an increase in the total return index, volatility index and solvency index.
D
Sell
3/25/2024Downgrade
Knight Therapeutics Inc. (GUD.TO) was downgraded to D- from D on 3/25/2024 due to a significant decline in the growth index, solvency index and volatility index. Earnings per share declined from $0.0671 to -$0.1759, EBIT declined 108.8% from $693.4 to -$61, and total revenue declined 10.25% from $60.76M to $54.54M.
Knight Therapeutics Inc. (GUD.TO) was downgraded to D- from D on 3/25/2024 due to a significant decline in the growth index, solvency index and volatility index. Earnings per share declined from $0.0671 to -$0.1759, EBIT declined 108.8% from $693.4 to -$61, and total revenue declined 10.25% from $60.76M to $54.54M.
D
Sell
1/26/2024Upgraded
Knight Therapeutics Inc. (GUD.TO) was upgraded to D from D- on 1/26/2024 due to a significant increase in the growth index, volatility index and total return index. Operating cash flow increased 1,122.15% from -$1.11M to $11.31M, EBIT increased 946.64% from -$81.9 to $693.4, and earnings per share increased from $0.0126 to $0.0671.
Knight Therapeutics Inc. (GUD.TO) was upgraded to D from D- on 1/26/2024 due to a significant increase in the growth index, volatility index and total return index. Operating cash flow increased 1,122.15% from -$1.11M to $11.31M, EBIT increased 946.64% from -$81.9 to $693.4, and earnings per share increased from $0.0126 to $0.0671.
D
Sell
10/6/2023Upgraded
Knight Therapeutics Inc. (GUD.TO) was upgraded to D- from E+ on 10/6/2023 due to an increase in the volatility index and total return index.
Knight Therapeutics Inc. (GUD.TO) was upgraded to D- from E+ on 10/6/2023 due to an increase in the volatility index and total return index.
E
Sell
9/21/2023Downgrade
Knight Therapeutics Inc. (GUD.TO) was downgraded to E+ from D- on 9/21/2023 due to a decline in the total return index, volatility index and solvency index.
Knight Therapeutics Inc. (GUD.TO) was downgraded to E+ from D- on 9/21/2023 due to a decline in the total return index, volatility index and solvency index.
D
Sell
8/14/2023Upgraded
Knight Therapeutics Inc. (GUD.TO) was upgraded to D- from E+ on 8/14/2023 due to a noticeable increase in the growth index, volatility index and solvency index. Earnings per share increased from -$0.0296 to $0.0126, total revenue increased 9.59% from $61.07M to $66.92M, and the quick ratio increased from 2.19 to 2.27.
Knight Therapeutics Inc. (GUD.TO) was upgraded to D- from E+ on 8/14/2023 due to a noticeable increase in the growth index, volatility index and solvency index. Earnings per share increased from -$0.0296 to $0.0126, total revenue increased 9.59% from $61.07M to $66.92M, and the quick ratio increased from 2.19 to 2.27.
E
Sell
5/26/2023Downgrade
Knight Therapeutics Inc. (GUD.TO) was downgraded to E+ from D- on 5/26/2023 due to a decline in the volatility index and total return index.
Knight Therapeutics Inc. (GUD.TO) was downgraded to E+ from D- on 5/26/2023 due to a decline in the volatility index and total return index.
D
Sell
5/22/2023Downgrade
Knight Therapeutics Inc. (GUD.TO) was downgraded to D- from D on 5/22/2023 due to a significant decline in the efficiency index, total return index and solvency index. Total capital declined 0.2% from $667.61M to $666.3M.
Knight Therapeutics Inc. (GUD.TO) was downgraded to D- from D on 5/22/2023 due to a significant decline in the efficiency index, total return index and solvency index. Total capital declined 0.2% from $667.61M to $666.3M.
D
Sell
5/16/2022Downgrade
Knight Therapeutics Inc. (GUD.TO) was downgraded to D from D+ on 5/16/2022 due to a significant decline in the valuation index and efficiency index. Net income declined 125.42% from -$6.59M to -$14.85M.
Knight Therapeutics Inc. (GUD.TO) was downgraded to D from D+ on 5/16/2022 due to a significant decline in the valuation index and efficiency index. Net income declined 125.42% from -$6.59M to -$14.85M.
D
Sell
11/15/2021Downgrade
Knight Therapeutics Inc. (GUD.TO) was downgraded to D+ from C- on 11/15/2021 due to a large decline in the valuation index, growth index and efficiency index. Earnings per share declined from $0.1873 to -$0.0556, net income declined 128.86% from $23.62M to -$6.81M, and operating cash flow declined 18.93% from $10.1M to $8.19M.
Knight Therapeutics Inc. (GUD.TO) was downgraded to D+ from C- on 11/15/2021 due to a large decline in the valuation index, growth index and efficiency index. Earnings per share declined from $0.1873 to -$0.0556, net income declined 128.86% from $23.62M to -$6.81M, and operating cash flow declined 18.93% from $10.1M to $8.19M.
C
Hold
11/5/2021Upgraded
Knight Therapeutics Inc. (GUD.TO) was upgraded to C- from D+ on 11/5/2021 due to a major increase in the valuation index, growth index and efficiency index. Earnings per share increased from $0.0218 to $0.1873, net income increased 740.21% from $2.81M to $23.62M, and EBIT increased 100.74% from -$1.77M to $13.
Knight Therapeutics Inc. (GUD.TO) was upgraded to C- from D+ on 11/5/2021 due to a major increase in the valuation index, growth index and efficiency index. Earnings per share increased from $0.0218 to $0.1873, net income increased 740.21% from $2.81M to $23.62M, and EBIT increased 100.74% from -$1.77M to $13.
D
Sell
11/16/2020Upgraded
Knight Therapeutics Inc. (GUD.TO) was upgraded to D+ from D on 11/16/2020 due to a significant increase in the valuation index, efficiency index and solvency index. The quick ratio increased from 1.97 to 4.66, debt to equity declined from 0.06 to 0.05, and net income increased 7.82% from $12.6M to $13.58M.
Knight Therapeutics Inc. (GUD.TO) was upgraded to D+ from D on 11/16/2020 due to a significant increase in the valuation index, efficiency index and solvency index. The quick ratio increased from 1.97 to 4.66, debt to equity declined from 0.06 to 0.05, and net income increased 7.82% from $12.6M to $13.58M.
D
Sell
6/26/2020Downgrade
Knight Therapeutics Inc. (GUD.TO) was downgraded to D from D+ on 6/26/2020 due to a noticeable decline in the efficiency index, valuation index and solvency index. Debt to equity increased from 0.07 to 0.08, and total capital declined 11.89% from $753.48M to $663.88M.
Knight Therapeutics Inc. (GUD.TO) was downgraded to D from D+ on 6/26/2020 due to a noticeable decline in the efficiency index, valuation index and solvency index. Debt to equity increased from 0.07 to 0.08, and total capital declined 11.89% from $753.48M to $663.88M.
D
Sell
6/4/2020Upgraded
Knight Therapeutics Inc. (GUD.TO) was upgraded to D+ from D on 6/4/2020 due to an increase in the total return index and valuation index.
Knight Therapeutics Inc. (GUD.TO) was upgraded to D+ from D on 6/4/2020 due to an increase in the total return index and valuation index.
D
Sell
5/20/2020Downgrade
Knight Therapeutics Inc. (GUD.TO) was downgraded to D from D+ on 5/20/2020 due to a large decline in the solvency index, growth index and efficiency index. Earnings per share declined from -$0.0163 to -$0.0402, net income declined 125.46% from -$2.24M to -$5.05M, and the quick ratio declined from 10.03 to 1.5.
Knight Therapeutics Inc. (GUD.TO) was downgraded to D from D+ on 5/20/2020 due to a large decline in the solvency index, growth index and efficiency index. Earnings per share declined from -$0.0163 to -$0.0402, net income declined 125.46% from -$2.24M to -$5.05M, and the quick ratio declined from 10.03 to 1.5.
D
Sell
2/25/2020Downgrade
Knight Therapeutics Inc. (GUD.TO) was downgraded to D+ from C- on 2/25/2020 due to a decline in the volatility index, total return index and efficiency index.
Knight Therapeutics Inc. (GUD.TO) was downgraded to D+ from C- on 2/25/2020 due to a decline in the volatility index, total return index and efficiency index.
C
Hold
11/14/2019Downgrade
Knight Therapeutics Inc. (GUD.TO) was downgraded to C- from C on 11/14/2019 due to a substantial decline in the valuation index, growth index and efficiency index. Earnings per share declined from $0.0987 to -$0.0163, net income declined 115.82% from $14.17M to -$2.24M, and total capital declined 9.66% from $802.04M to $724.54M.
Knight Therapeutics Inc. (GUD.TO) was downgraded to C- from C on 11/14/2019 due to a substantial decline in the valuation index, growth index and efficiency index. Earnings per share declined from $0.0987 to -$0.0163, net income declined 115.82% from $14.17M to -$2.24M, and total capital declined 9.66% from $802.04M to $724.54M.
C
Hold
8/13/2019Upgraded
Knight Therapeutics Inc. (GUD.TO) was upgraded to C from C- on 8/13/2019 due to an increase in the valuation index, efficiency index and solvency index. Net income increased 263.04% from $3.9M to $14.17M, and total capital increased 3.71% from $773.34M to $802.04M.
Knight Therapeutics Inc. (GUD.TO) was upgraded to C from C- on 8/13/2019 due to an increase in the valuation index, efficiency index and solvency index. Net income increased 263.04% from $3.9M to $14.17M, and total capital increased 3.71% from $773.34M to $802.04M.
C
Hold
3/29/2019Downgrade
Knight Therapeutics Inc. (GUD.TO) was downgraded to C- from C on 3/29/2019 due to a noticeable decline in the volatility index, total return index and solvency index. The quick ratio declined from 42.49 to 41.18.
Knight Therapeutics Inc. (GUD.TO) was downgraded to C- from C on 3/29/2019 due to a noticeable decline in the volatility index, total return index and solvency index. The quick ratio declined from 42.49 to 41.18.
C
Hold
8/3/2018Upgraded
Knight Therapeutics Inc. (GUD.TO) was upgraded to C from C- on 8/3/2018 due to a noticeable increase in the volatility index.
Knight Therapeutics Inc. (GUD.TO) was upgraded to C from C- on 8/3/2018 due to a noticeable increase in the volatility index.
C
Hold
1/11/2018Downgrade
Knight Therapeutics Inc. (GUD.TO) was downgraded to C- from C on 1/11/2018 due to a substantial decline in the volatility index, total return index and growth index. Total revenue declined 19.52% from $1.84M to $1.48M, and EBIT declined 8.35% from -$1.9M to -$2.06M.
Knight Therapeutics Inc. (GUD.TO) was downgraded to C- from C on 1/11/2018 due to a substantial decline in the volatility index, total return index and growth index. Total revenue declined 19.52% from $1.84M to $1.48M, and EBIT declined 8.35% from -$1.9M to -$2.06M.
C
Hold
5/17/2017Downgrade
Knight Therapeutics Inc. (GUD.TO) was downgraded to C from C+ on 5/17/2017 due to a noticeable decline in the total return index.
Knight Therapeutics Inc. (GUD.TO) was downgraded to C from C+ on 5/17/2017 due to a noticeable decline in the total return index.
C
Hold
4/28/2017Upgraded
Knight Therapeutics Inc. (GUD.TO) was upgraded to C+ from C on 4/28/2017 due to an increase in the volatility index.
Knight Therapeutics Inc. (GUD.TO) was upgraded to C+ from C on 4/28/2017 due to an increase in the volatility index.
C
Hold
3/21/2017Downgrade
Knight Therapeutics Inc. (GUD.TO) was downgraded to C from B- on 3/21/2017 due to a noticeable decline in the total return index, growth index and volatility index. EBIT declined 74.2% from -$1.07M to -$1.86M, operating cash flow declined 39% from $3.36M to $2.05M, and total revenue declined 4.5% from $1.45M to $1.38M.
Knight Therapeutics Inc. (GUD.TO) was downgraded to C from B- on 3/21/2017 due to a noticeable decline in the total return index, growth index and volatility index. EBIT declined 74.2% from -$1.07M to -$1.86M, operating cash flow declined 39% from $3.36M to $2.05M, and total revenue declined 4.5% from $1.45M to $1.38M.
B
Buy
3/7/2017Upgraded
Knight Therapeutics Inc. (GUD.TO) was upgraded to B- from C+ on 3/7/2017 due to a large increase in the total return index and volatility index.
Knight Therapeutics Inc. (GUD.TO) was upgraded to B- from C+ on 3/7/2017 due to a large increase in the total return index and volatility index.
C
Hold
11/18/2016Upgraded
Knight Therapeutics Inc. (GUD.TO) was upgraded to C+ from C on 11/18/2016 due to a significant increase in the total return index, growth index and volatility index. Total revenue increased 64.57% from $881 to $1.45M, EBIT increased 39.33% from -$1.76M to -$1.07M, and earnings per share increased from $0.0306 to $0.0307.
Knight Therapeutics Inc. (GUD.TO) was upgraded to C+ from C on 11/18/2016 due to a significant increase in the total return index, growth index and volatility index. Total revenue increased 64.57% from $881 to $1.45M, EBIT increased 39.33% from -$1.76M to -$1.07M, and earnings per share increased from $0.0306 to $0.0307.
C
Hold
4/1/2016Upgraded
Knight Therapeutics Inc. (GUD.TO) was upgraded to C from C- on 4/1/2016 due to an increase in the efficiency index.
Knight Therapeutics Inc. (GUD.TO) was upgraded to C from C- on 4/1/2016 due to an increase in the efficiency index.
C
Hold
1/4/2016Upgraded
Knight Therapeutics Inc. (GUD.TO) was upgraded to C- from D+ on 1/4/2016 due to a major increase in the volatility index, growth index and total return index. EBIT increased 34.12% from -$2.21M to -$2.96M, and operating cash flow increased 9.97% from -$677.7 to -$745.3.
Knight Therapeutics Inc. (GUD.TO) was upgraded to C- from D+ on 1/4/2016 due to a major increase in the volatility index, growth index and total return index. EBIT increased 34.12% from -$2.21M to -$2.96M, and operating cash flow increased 9.97% from -$677.7 to -$745.3.
D
Sell
10/1/2015Upgraded
Knight Therapeutics Inc. (GUD.TO) was upgraded to D+ from D on 10/1/2015 due to an increase in the growth index, solvency index and efficiency index. The quick ratio increased from 76.11 to 117.36, total revenue increased 35.78% from $199.3 to $270.6, and EBIT increased 7.11% from -$2.06M to -$2.21M.
Knight Therapeutics Inc. (GUD.TO) was upgraded to D+ from D on 10/1/2015 due to an increase in the growth index, solvency index and efficiency index. The quick ratio increased from 76.11 to 117.36, total revenue increased 35.78% from $199.3 to $270.6, and EBIT increased 7.11% from -$2.06M to -$2.21M.
D
Sell
6/11/2015Downgrade
Knight Therapeutics Inc. (GUD.TO) was downgraded to D from D+ on 6/11/2015 due to a decline in the volatility index.
Knight Therapeutics Inc. (GUD.TO) was downgraded to D from D+ on 6/11/2015 due to a decline in the volatility index.
D
Sell
5/27/2015Upgraded
Knight Therapeutics Inc. (GUD.TO) was upgraded to D+ from D on 5/27/2015 due to a major increase in the volatility index and valuation index.
Knight Therapeutics Inc. (GUD.TO) was upgraded to D+ from D on 5/27/2015 due to a major increase in the volatility index and valuation index.
D
Sell
4/1/2015Upgraded
Knight Therapeutics Inc. (GUD.TO) was upgraded to D from D- on 4/1/2015 due to a significant increase in the valuation index, efficiency index and volatility index. Net income increased 21,201.03% from $516.7 to $110.06M, and total capital increased 77.45% from $233.09M to $413.61M.
Knight Therapeutics Inc. (GUD.TO) was upgraded to D from D- on 4/1/2015 due to a significant increase in the valuation index, efficiency index and volatility index. Net income increased 21,201.03% from $516.7 to $110.06M, and total capital increased 77.45% from $233.09M to $413.61M.
D
Sell
12/1/2014Upgraded
Knight Therapeutics Inc. (GUD.TO) was upgraded to D- from E+ on 12/1/2014 due to an increase in the total return index and volatility index.
Knight Therapeutics Inc. (GUD.TO) was upgraded to D- from E+ on 12/1/2014 due to an increase in the total return index and volatility index.
E
Sell
11/20/2014None
Knight Therapeutics Inc. (GUD.TO) was downgraded to E+ from U on 11/20/2014.
Knight Therapeutics Inc. (GUD.TO) was downgraded to E+ from U on 11/20/2014.
